Company ProfilePremium

Trust Chem Co. Ltd.

Company Profile Analysis

Ticker: 001335.SZ浙江信凯科技集团股份有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Trust Chem Co. Ltd. - Company showcase

Year Founded & Workforce

1996

445 Employees

Trust Chem Co. Ltd. logo

Trust Chem Co. Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Trust Chem Co. Ltd. Overview

Trust Chem is China's largest exporter of organic pigments, ranked first in national organic-pigment exports every year from 2015 to 2025 by the Organic Pigment Committee of the China Dyestuff Industry Association. Historically an asset-light "colourant solutions" house, it combines application-driven product development, proprietary testing and quality control, upstream supply-chain integration and a global, localised sales and warehousing network across 70–80+ countries, selling more than 450 pigment specifications under its own brand to multinational ink, coating and plastics producers such as DIC, Flint Group, Siegwerk, Sherwin-Williams and Axalta. Roughly 80–88% of revenue is earned outside China. Since 2023 it has been moving upstream into owned manufacturing through two subsidiaries in Jinzhou, Liaoning, and its July 2026 convertible-bond plan (≤ CNY 450M) would fund high-performance post-treatment capacity. The investment case hinges on whether vertical integration can lift structurally thin (~15–18%) gross margins without eroding its trading-model agility.


Company's own description (2026 Interim Report, Section III)

The company states that it is principally engaged in the product development, production, sale and servicing of organic pigments and other colourants. Its core competitiveness is defined as product development, quality management, supply-chain integration and a global sales network. Main products are organic pigments (azo, heterocyclic, phthalocyanine and others) and acid dyes. Organic pigments are applied in inks, coatings, plastics and specialty applications; acid dyes are used for dyeing textile fibres (nylon, wool, silk and blends), inkjet inks and waterborne wood lacquers. The company emphasises that downstream application diversity, customer habits and regional differences create extensive demand for customised and personalised pigment products, and that large international customers impose stringent requirements on application development capability, quality, management systems, compliance, geographic coverage and responsiveness.

The stated operating model is a five-link chain: (1) obtain and analyse customer requirements; (2) develop products; (3) manage the supply chain; (4) test products and control quality; (5) sell under the company's own brand.

Operating sub-models

Procurement: Because no single pigment manufacturer can cover the breadth of downstream needs, Trust Chem integrates upstream suppliers who produce to its specifications, and maintains a "qualified supplier list" refreshed through periodic assessments. Per the IPO risk disclosure, purchased finished pigments accounted for 94.88% (FY2021), 93.05% (FY2022), 93.64% (FY2023) and 88.94% (1H2024) of main-business cost — demonstrating that the company has been overwhelmingly a branded integrator rather than a manufacturer.

Sales: Predominantly export-led, combining a Hangzhou headquarters sales team with localised overseas teams. Orders flow through an ERP system to procurement and technical service; product-development requests go to R&D. The company maintains overseas warehousing so it can serve safety-stock requirements and deliver quickly.

R&D: A synthesis laboratory (new pigment development) and application laboratories for coatings, plastics and inks that simulate customers' use conditions. New-product development follows a project-team model led by R&D with multi-department participation, staged from demand investigation through feasibility, design, sampling, testing, review and acceptance.

Own production: Described as a "supplement and improvement" to the supply chain — validating R&D projects at the company's own production bases before supply. The Jinzhou (Liaoning) bases are positioned in the CB filings as the group's "technology transformation base for high-quality, high-value-added, safer and more environmentally friendly products."

Revenue model and mix

DimensionCharacterisation
Product vs. service~99% product sales (chemical industry); "other business" 0.96% of 1H2026 revenue
Subscription / licensingNone disclosed
Pricing basisTransactional, quoted in USD/EUR for exports; forward FX quoting used to pass through currency risk
Revenue recognitionFOB/CIF/CFR on bill of lading; DDU/DAP/DDP on customer receipt; consignment on monthly reconciliation (2026 Interim Report, Note V.37)
Customer concentrationTop-5 receivables = 32.66% of receivables at 30 Jun 2026 (largest 12.47%)

Value-chain position

Trust Chem sits between Chinese pigment producers (upstream: petrochemical and coal-chemical intermediates → pigment synthesis) and multinational formulators (downstream: printing inks, industrial and decorative coatings, plastics masterbatch). Its value-add is specification design, application testing, regulatory compliance (REACH, MSDS in ~30 languages), brand assurance and logistics. It is now adding a manufacturing layer (azo dyes/pigments and high-quality organic pigments in Jinzhou) and, if the CB is completed, a post-treatment ("high-performance-isation") layer that would upgrade both self-made and outsourced pigments.

Customer types and end-markets

End-marketApplicationRepresentative customers named in filings
Printing inksPackaging, publication, specialty inksDIC Corporation, Flint Group, Siegwerk
CoatingsIndustrial, decorative, automotive refinishSherwin-Williams, Axalta
PlasticsMasterbatch, compoundsNot named
Textiles (acid dyes)Nylon, wool, silk dyeingNot named
SpecialtyInkjet inks, waterborne wood lacquers, stationeryNot named

The CB feasibility report (Jul 2026) states core customer relationships exceed ten years and switching costs are high.

Independent characterisation

Trust Chem is best understood as a global specialty-chemicals distributor-integrator with brand and compliance moats, in transition toward partial vertical integration. Its gross margins (~14–18%) are closer to a sophisticated distributor than to a pigment manufacturer (domestic HPP producers such as Qicai Chemical report ~29% gross margin), but its returns on equity were historically high (derived ~17–22% in FY2022–FY2024) because the model was capital-light. The pivot to owned manufacturing in Liaoning has raised the asset base (total assets up from CNY 983M in FY2021 to CNY 2,026M at 1H2026) while the manufacturing subsidiaries have so far been loss-making (Liaoning Xinkai net loss CNY 24.97M in FY2024), compressing ROE (derived ~9.5% in FY2025). The core strategic question for investors is therefore one of capital allocation: whether manufacturing brings margin uplift and supply security commensurate with the capital and execution risk.

Strategy

Stated strategy themes (2026 Interim Report; CB filings)

The company frames its strategy around four pillars, paraphrased from filings:

  1. High-end manufacturing upgrade — moving from supply-chain integration to selective owned production and post-treatment to raise value added and margins ("提升高端化生产制造能力").

  2. Globalised marketing and service network — deepening localised sales teams, warehousing and logistics to increase customer stickiness.

  3. Digital and intelligent group platform — rebuilding a global ERP to integrate R&D, manufacturing, logistics and finance across 15 entities, and preparing for AI tooling.

  4. Green and compliant growth — leveraging REACH registrations and EHS systems as market-access barriers, and building owned environmental infrastructure.

Press coverage of the 1H2025 results describes management's narrative as "globalisation and green transformation dual-wheel drive", pointing to stricter EU REACH restrictions and US supply-chain scrutiny as forces accelerating the shift toward high-end, green pigments.

Initiatives in the last 24 months

InitiativeDateScope / targetStatus
IPO and use of proceedsApr 2025CNY 243.85M net: R&D Centre & HQ (CNY 164.63M) and bank loan repayment (CNY 79.23M)73.3% of proceeds used at 30 Jun 2026; loan repayment complete; R&D centre 68% complete, delayed to Jun 2027
1,500 t high-quality organic pigment projectOngoingBudget CNY 229.99M; self-funded and bank loans92.31% complete (1H2026)
Liaoning Xinkai 10,000 t azo dye/pigment projectCommissioned ~2023Supported by CNY 28.16M subsidyRamping; subsidiary loss-making in FY2024
Shanghai logistics centre leaseJun 20255,500 m², three yearsOperating
Convertible bond (≤ CNY 450M)Announced 7 Jul 2026Five projects (see below)Pending shareholder approval/exchange review/CSRC registration
FX hedging programmeRenewed Apr–May 2026Forward contracts matched to receiptsOngoing; CNY 0.39M realised gain 1H2026
CNY 1.2bn bank credit lineApproved Jun 2025Group-wide revolving facilitiesOngoing
ProjectTotal investment (CNY Mn)Proceeds (CNY Mn)ImplementerNotes
Dye/pigment high-performance post-treatment project230.0230.0Liaoning XinkaiConstruction CNY 215M + working capital CNY 15M; Jinzhou; land secured; filing and EIA in progress
1,500 t/day wastewater treatment project45.045.0Liaoning ZiyuanWithin existing site; no direct profit
Global marketing service network upgrade80.080.0Parent, Trust Chem Europe, Trust Chem USAWarehouse leasing CNY 53M, personnel CNY 15M, equipment CNY 12M
Global digital/intelligent ERP system20.020.0ParentDevelopment CNY 10M, hardware CNY 5M, licences CNY 5M
Bank loan repayment75.075.0ParentAgainst ~CNY 336M bank loans
Total450.0450.0——

Sustainability/ESG commitments

No quantified emissions targets or ESG commitments were found in the filings reviewed. The wastewater project and the "safer, more environmentally friendly products" positioning of the Liaoning base are the main environmental initiatives.

Medium-term financial targets / guidance

Management has not published revenue, margin or earnings guidance. The CB dilution announcement uses illustrative scenarios (flat, +10% and +20% annual growth in net profit from the FY2025 base of CNY 77.82M) explicitly stated not to constitute forecasts. The company has not adopted a market-value management system or a valuation enhancement plan, and has not published a "quality and returns dual improvement" action plan (2026 Interim Report).

Products & Services

Azo pigments (60.3% of 1H2026 revenue)

Description: Azo-based organic pigments, which include most "classic organic pigments" (CLP): lake pigments, naphthol (色酚) types, diarylide (benzidine) yellows, pyrazolones and monoazo yellows (company glossary).

Key properties: High tinting strength, bright shades, ease of grinding and dispersion; fastness (weather and light) inferior to high-performance pigments (HPP).

Target customers: Printing-ink manufacturers (packaging and publication), indoor coatings, plastics.

Capacity: Liaoning Xinkai's 10,000-tonne azo dye/pigment project (commissioning from ~Oct 2023; ramp ongoing).

Gross margin: 18.09% (1H2026); 15.14% (FY2025); 13.92% (FY2024).

Pricing model: Transactional, USD/EUR quotation; not disclosed.

Heterocyclic pigments (22.4% of 1H2026 revenue)

Description: Heterocyclic-structure pigments generally belonging to the high-performance class (company does not name sub-families in the documents reviewed; industry classification typically includes quinacridones, diketopyrrolopyrroles, dioxazines, isoindolines and similar).

Key properties (HPP glossary): Superior lightfastness, weatherfastness, heat resistance and solvent resistance; strong application performance (dispersion, rheology, storage stability); priced above CLP.

Target customers: Industrial and automotive coatings, outdoor plastics.

Gross margin: 19.04% (1H2026); 17.70% (FY2025); 18.24% (FY2024).

Momentum: Fastest-growing major line (+31.1% in 1H2026).

Phthalocyanine pigments (3.9% of 1H2026 revenue)

Description: Copper-phthalocyanine blues and greens.

Applications: Inks, coatings, plastics.

Trend: Revenue −7.7% in 1H2026 to CNY 31.09M. Margin not disclosed.

Other organic pigments (5.3% of 1H2026 revenue)

Description: Organic pigments outside the three main chemistries (not itemised).

Trend: +36.2% in 1H2026 to CNY 42.13M.

Acid dyes and other main business (7.1% of 1H2026 revenue)

Description: Acid dyes for nylon, wool, silk and blended fabrics; inkjet ink colourants; waterborne wood-lacquer colourants (2026 Interim Report).

Trend: "Other main business" +64.4% in 1H2026 to CNY 56.43M.

Services and capabilities bundled with products

CapabilitySpecificationSource
Portfolio breadth450+ pigment specifications2026 Interim Report
Testing200+ test methods; grinding/dispersion equipment simulating customer production2026 Interim Report
Application labsCoatings, plastics and ink application laboratories2026 Interim Report
Regulatory89 EU REACH registrations completed in-house; MSDS in ~30 languages (EN, FR, DE, ES, PT, KO, JA and others); EHS team for 15+ years2026 Interim Report
LogisticsShanghai logistics centre (5,500 m² lease); warehouses in US, Canada, Netherlands, Turkey, UK, Australia2026 Interim Report
CustomisationApplication-specific development with customer co-testing2026 Interim Report
Core technologiesOrganic-pigment surface treatment; organic-pigment testing; control of negative (restricted) substances2026 Interim Report

Pipeline products

The proposed CB-funded "dye/pigment high-performance post-treatment" project (CNY 230M, Jinzhou) would apply finishing processes to both self-produced and outsourced pigments to improve weatherfastness and tinting strength — effectively a margin-enhancement service layer on the existing product range rather than new chemistry. Liaoning Xinkai is reported to be "gradually launching new products with good validation feedback from downstream customers" (CB feasibility report, Jul 2026); specific products are not named.

Financial Narrative

Sources: FY2021 — IPO prospectus summary (Jiemian / prospectus data table); FY2022–FY2024 — audited data in IPO listing announcement (15 Apr 2025); FY2025 — CB dilution announcement (Jul 2026), Eastmoney, and opening balances of the 2026 Interim Report; 1H data — 2026 Interim Report. All CNY M.

Income statement

FY2025 revenue is derived from the reported 7.33% decline on FY2024 (Eastmoney reports CNY 1.313bn). FY2025 operating profit, EBITDA and pre-tax income were not available in the sources reviewed.

FY2025 basic EPS on the weighted share count is not confirmed; using the aggregator's FY2025 deducted EPS of CNY 0.97 implies a weighted share base of ~85.6M and basic EPS of ~CNY 0.91 (derived). Diluted EPS equals basic (no dilutive instruments outstanding). FY2024 and FY2025 dividends: CNY 1.50 per 10 shares (CNY 14.06M each), per the 2024 profit distribution announcement and the 1H2026 equity statement.

FY2024 gross margin of 14.34% is from moomoo key indicators (secondary, reported as of Apr 2025). Company-level gross margin for 1H2026 is 18.27% (derived: revenue 791.58 less cost 646.92) versus 16.25% for 1H2025.

Revenue CAGR FY2021–FY2025 (derived): ~2.1% per annum. Revenue is essentially flat across the period, with a cyclical trough in FY2023 (destocking across global ink and coatings chains) and a peak in FY2024.

Interim comparison (2026 Interim Report)

Commentary: The 1H2026 print shows strong operational momentum masked by currency. Gross profit rose 27% and opex fell, but a CNY 36M swing in finance costs — from a CNY 17.2M gain to an CNY 18.9M charge, which the company attributes mainly to RMB appreciation against USD and EUR — wiped out the operating gain. Inventory write-downs doubled to CNY 8.0M. EPS fell 16% because of the full-period effect of the IPO share issuance.

Balance sheet

1H2026 balance sheet (30 Jun 2026): Total assets CNY 2,026.09M; cash CNY 394.03M (of which CNY 99.94M restricted — acceptance-bill margins, FX forward margins, pledged deposits and a litigation freeze); receivables CNY 294.41M; inventory CNY 382.58M; long-term equity investments CNY 91.26M; fixed assets CNY 506.01M; construction in progress CNY 97.27M; short-term borrowings CNY 180.99M; long-term borrowings CNY 133.28M; current portion of non-current liabilities CNY 32.45M; notes payable CNY 344.35M; accounts payable CNY 206.03M; total liabilities CNY 963.64M; attributable equity CNY 1,008.15M; minority interests CNY 54.29M. Goodwill: nil. The company states bank loans totalled ~CNY 336M at 30 Jun 2026 (CB feasibility report).

Note: CNY 344M of bank acceptance notes payable is a significant quasi-financing item excluded from the above; including it would put the group in a net-debt position of roughly CNY 386M at 1H2026 (derived).

Cash flow

Capex was not separately captured for FY2022–FY2025, but investing outflows of CNY 124–160M per year during FY2022–FY2024 are consistent with the Liaoning build-out. No share buybacks have been authorised or executed. 1Q2026 operating cash flow was −CNY 31.92M (Eastmoney).

Ratios

Notes: FY2025 ROA uses attributable net income (total net income not captured). 1Q2026 current ratio 1.57x, quick ratio 1.03x, liabilities-to-assets 45.34% (CB plan). Cash conversion cycle at 1H2026: 12.67 days (Lixinger, secondary), with receivable days ~58. ROIC and net debt/EBITDA are not publicly disclosed and cannot be robustly derived because FY2025 EBITDA was not available; on FY2024 data the group was near net-neutral on bank debt.

Trend commentary

Growth: The top line has been range-bound at CNY 1.07–1.42bn for five years. FY2024's 32.5% surge reflected post-destocking restocking by multinational customers and new Liaoning output; FY2025's 7.3% decline reflected weaker export pricing and US tariff friction. 1H2026's 13.2% rebound — led by domestic sales (+70%) and heterocyclic pigments (+31%) — suggests FY2026 revenue could recover toward FY2024 levels, though management provides no guidance.

Profitability: Attributable net margins have been remarkably stable at 7.3–8.2% (FY2021–FY2024) before falling to 5.9% in FY2025. The FY2025 compression is explained by lower revenue, losses at the Liaoning manufacturing subsidiaries, and FX. Notably, FY2025 deducted net profit (CNY 83.0M) exceeded reported net profit (CNY 77.8M), meaning non-recurring items (principally FX derivative fair-value losses) were a net drag.

Balance sheet: The IPO (net proceeds CNY 243.85M) de-levered the group from 58% to 46% liabilities-to-assets. However, the company is now re-levering (short-term borrowings up 70% in 1H2026) to fund working capital and capex, and plans a CNY 450M CB — a sign that the IPO raise was undersized relative to the manufacturing ambition (the company itself describes the prior raise as "relatively small and basically used up").

Cash flow: Operating cash flow covered net income in FY2022–FY2024 (cash conversion ~0.9–1.4x), but capex has consistently exceeded OCF, producing negative free cash flow during the build-out.

FX sensitivity: Exchange gains/losses swing materially: FY2021 loss CNY 10.94M; FY2022 gain CNY 13.73M; FY2023 gain CNY 8.32M; 1H2024 gain CNY 3.78M; 1H2026 net finance charge of CNY 18.90M mainly from FX. On a 1H2026 pre-tax profit of CNY 65M, a CNY 36M year-on-year FX swing is highly material.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Product Lines

Product line (CNY Mn)FY2023FY2024FY2025

Azo pigments revenue

721903847

Heterocyclic pigments revenue

—285259

All other lines incl. phthalocyanine, other pigments, acid dyes, other business (derived residual)

—229207

Total operating revenue

1,0691,4171,313

Product line gross margin (%)

Product line gross margin (%)FY2023FY2024FY2025

Azo pigments gross margin

15.6113.9215.14

Heterocyclic pigments gross margin

17.6218.2417.70

Product line share of revenue (%)

Product line share of revenue (%)FY2023FY2024FY2025

Azo pigments share

67.4263.7764.52

Heterocyclic pigments share

—20.0819.76

Product line YoY growth (%)

Product line YoY growth (%)FY2024FY2025

Azo pigments YoY

25.2-6.2

Heterocyclic pigments YoY

—-9.1

Total revenue YoY

32.5-7.3

Product Lines (1H2025–1H2026)

Product line (CNY Mn)1H20251H2026

Azo pigments

458.50477.35

Heterocyclic pigments

134.95176.94

Phthalocyanine pigments

33.6931.09

Other organic pigments

30.9442.13

Other main business (incl. acid dyes)

34.3456.43

Other business

6.667.63

Total

699.08791.58

Product line (1H2026)

Revenue share %

YoY %

Azo pigments

60.30+4.11

Heterocyclic pigments

22.35+31.11

Phthalocyanine pigments

3.93−7.72

Other organic pigments

5.32+36.17

Other main business

7.13+64.35

Chemical industry total

99.04+13.22

Group Entities

EntityLocationOwnershipFunction

Zhejiang Haochuan Technology Co., Ltd. (浩川科技)

Zhejiang

Controlled

R&D; provincial-level HNTE R&D centre; 15% tax rate

Shanghai Canglong Supply Chain Management Co., Ltd. (上海仓隆)

Shanghai

Controlled

Supply chain/logistics; small-profit enterprise

Liaoning Xinkai Industrial Co., Ltd. (辽宁信凯)

Jinzhou, Liaoning

74.60%

Manufacturing — azo dyes/pigments (10,000 t project); environmental-disclosure-listed entity

Liaoning Xinkai Ziyuan New Materials Co., Ltd. (辽宁紫源)

Jinzhou Binhai New Area, Liaoning

79% (21% Wuxi Wucai Industrial Investment LP)

Pigment manufacturing; registered capital CNY 150M

Hangzhou Yuancai Enterprise Management LP (杭州源彩)

Hangzhou

Controlled partnership

Holding/incentive vehicle

Trust Chem Hong Kong Ltd.

Hong Kong

Controlled

Trading/holding (USD functional)

TCC Development Hong Kong Ltd.

Hong Kong

Controlled

Holding (USD functional)

Worldwide Colorants & Chemical Co., Ltd.

Hong Kong

Controlled

Trading brand entity (USD functional)

Trust Chem Europe B.V.

Netherlands

Controlled

Sales, warehousing (EUR)

Trust Chem USA, LLC

United States

Controlled

Sales, warehousing (USD)

Trust Chem Canada Ltd.

Canada

Controlled

Sales, warehousing

Worldwide Colorants and Chemicals Australia Pty Ltd.

Australia

Controlled

Sales, warehousing

Trust Chem Pigments Private Ltd.

India

Controlled

Sales (INR)

Trust Chem Turkey Pigment Ltd. Şti.

Turkey

Controlled

Sales, warehousing (TRY)

Trust Chem UK Pigments Ltd.

United Kingdom

Controlled

Sales, warehousing (GBP)

Wenzhou Jinyuan New Material Technology Co., Ltd. (温州金源)

Wenzhou, Zhejiang

Associate (equity method)

Pigment production; key related-party supplier; financials exempted from disclosure

Group Entities by Subsidiary

SubsidiaryTotal assetsNet assetsRevenueOperating profitNet profit

Trust Chem Europe B.V.

173.0114.21169.2216.4112.28

Trust Chem USA, LLC

125.7831.55146.698.736.52

Results by Segment and Segment Assets & Liabilities

Liaoning Xinkai Industrial (CNY Mn)FY2024 (audited)1Q2025 (unaudited)

Revenue

100.5636.31

Total profit

-33.75-8.09

Net profit

-24.97-6.08

Total liabilities

282.74319.25

Net assets

148.73142.65

Income statement (CNY Mn)

Income statement (CNY Mn)FY2021FY2022FY2023FY2024FY2025

Revenue

1,205.671,192.391,068.721,416.571,312.75

Operating profit

—110.03104.27131.56—

EBITDA (company-defined)

—124.97122.44167.42—

Pre-tax income

—113.39104.39131.52—

Net income (total)

—85.3184.55104.85—

Net income attributable to parent

89.0287.6588.06110.9777.82

Attributable net income excl. non-recurring items

—91.0983.44104.9183.02

Per-share data (CNY)

Per-share data (CNY)FY2022FY2023FY2024FY2025

Basic EPS (derived; pre-IPO share count 70.30M)

1.251.251.58—

Basic EPS excl. non-recurring (reported/aggregator)

—1.181.490.97

Dividend per share

——0.150.15

Margins (%)

Margins (%)FY2021FY2022FY2023FY2024FY2025

Gross margin (company-level)

———14.34—

Operating margin (derived)

—9.239.769.29—

EBITDA margin (derived)

—10.4811.4611.82—

Net margin attributable (derived)

7.387.358.247.835.93

Income Statement and Per-Share Data

Line item (CNY Mn)1H20251H2026YoY %

Revenue

699.08791.58+13.23

Cost of sales

585.49646.92+10.49

Gross profit (derived)

113.59144.66+27.4

Selling expenses

30.9629.87−3.53

Administrative expenses

25.2021.87−13.21

R&D expenses

3.607.71+114.06

Finance costs (net)

−17.2418.90—

— of which interest expense

3.264.78+46.5

Investment income (mainly associate)

11.5410.16−12.0

Fair-value gains

−10.892.06—

Credit impairment

−2.07−4.90—

Asset (inventory) impairment

−3.63−8.04—

Operating profit

65.2764.71−0.86

Total profit

65.3465.10−0.36

Income tax

14.3412.99−9.45

Net profit attributable

54.5755.07+0.92

Net profit attributable excl. non-recurring

61.3252.55−14.29

Basic EPS (CNY)

0.700.59−15.71

Weighted ROE (%)

7.055.52−1.53pp

Balance Sheet

Balance sheet (CNY Mn)FY2021FY2022FY2023FY2024FY2025

Total assets

983.451,083.141,332.341,753.901,893.91

Current assets

—670.41753.30998.021,056.64

Current liabilities

—507.61569.29835.15711.34

Working capital (derived)

—162.81184.01162.87345.30

Cash and equivalents (monetary funds)

———371.99309.22

Inventory

———338.55379.90

Accounts receivable

———221.52213.48

Short-term borrowings

————106.74

Long-term borrowings

————108.67

Notes payable (bank acceptances)

————379.93

Total liabilities

—572.81714.211,020.14862.56

Total equity

—510.34618.13733.761,031.35

Equity attributable to parent

351.89454.38549.59664.75972.30

Goodwill

————0

Intangible assets (mainly land use rights)

————84.43

Net debt (CNY Mn, derived)

Net debt (CNY Mn, derived)FY20251H2026

Bank borrowings (ST + LT + current portion, approx.)

232336

Cash (gross)

309394

Net debt (negative = net cash), gross cash basis

-77-58

Net debt excluding restricted cash

—42

Cash flow (CNY Mn)

Cash flow (CNY Mn)FY2022FY2023FY2024FY2025

Operating cash flow

102.99121.2694.73—

Investing cash flow

-159.80-124.32-153.66—

Financing cash flow

22.0433.8993.59—

FX effect on cash

17.498.8312.73—

Net change in cash

-17.2839.6647.40—

Dividends paid to parent shareholders

———14.06

Cash flow (CNY Mn) (1H2025–1H2026)

Cash flow (CNY Mn)1H20251H2026

Operating cash flow

-37.9339.67

Capex (purchase of PP&E/intangibles)

30.9168.66

Free cash flow (derived, OCF − capex)

-68.84-28.99

Investing cash flow

-50.31-15.58

Financing cash flow

195.9093.43

Dividends and interest paid

4.9720.07

FX effect on cash

6.84-14.66

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE on avg attributable equity (%, derived)

21.717.518.39.5

ROA on avg total assets (%, derived)

8.37.06.84.3

Current ratio (x)

1.321.321.201.49

Quick ratio (x)

0.910.940.790.95

Liabilities-to-assets (%)

52.8853.6158.1645.54

Total liabilities / total equity (x, derived)

1.121.161.390.84

Interest coverage (x)

22.0520.2317.11—

Asset turnover (x)

1.150.880.92—

Receivables turnover (x)

5.855.506.65—

Inventory turnover (x)

4.654.194.36—

Overseas share of main-business revenue (%)

Overseas share of main-business revenue (%)FY2021FY2022FY2023

Overseas share

84.9086.4588.20

United States share

9.3313.0213.67

Revenue by Region

Region (CNY Mn)1H20251H2026

Domestic main-business revenue

86.45147.12

Overseas main-business revenue

605.97636.83

Other business

6.667.63

Region (1H2026)

Share of revenue %

YoY %

Domestic

18.59+70.18

Overseas

80.45+5.09

Share Price & Returns

Reference pointPrice (CNY)Implied return to CNY 33.32 (1 Sep 2026)

IPO issue price (Apr 2025)

12.80+160%

First-day open (15 Apr 2025)

51.00−35%

52-week high (to Aug 2026)

58.68−43%

52-week low (to Aug 2026)

26.95+24%

Approx. start of 2026 (derived from −30.91% YTD at CNY 33.97 on 8 Jul 2026)

~49.2

−32%

Period return

Value

—

1-year (to 9 Aug 2026)

−18.99% (Investing.com)

—

3-year

n/a (listed Apr 2025)

—

5-year

n/a (listed Apr 2025)

—

Annualised since listing (to 1 Sep 2026)

−18.71% (Lixinger, measured from first trading price)

—

Valuation Multiples

MultipleTrust ChemLily GroupQicai ChemicalBasis

P/E (TTM)

39.9

~147 (dynamic)

~58 (dynamic)

Lixinger; 10jqka (Jul 2026)

P/B

3.1010.102.04

Same

EV/Sales (TTM, derived)

~2.2

not computed

not computed

EV ≈ CNY 3.12bn; TTM revenue CNY 1.405bn

Dividend yield

0.45%——

Lixinger

Dividend (CNY)

Dividend (CNY)FY2024FY2025

DPS

0.150.15

Total cash dividend (CNY Mn)

14.0614.06

Payout ratio (%, derived)

12.718.1

Capital Markets

Item (30 Jun 2026)CNY Mn

Short-term borrowings

180.99

Current portion of non-current liabilities

32.45

Long-term borrowings

133.28

Lease liabilities (non-current)

2.55

Notes payable (bank acceptances, ≤1 year)

344.35

Shares by Date

DateShares% of totalHolders

15 Oct 2025 (expired)

471,2690.50

Offline placement investors

15 Apr 2026 (expired)

2,109,1402.25

Ningbo Huikai Century VC

15 Apr 2028

68,195,53072.75

Senyuan, Li Zhi, Li Wu, Lishijia

Analyst Conclusions

Management guidance

No formal guidance. Management's qualitative signals (2026 Interim Report; CB filings): continued globalisation and manufacturing upgrade, partial pass-through of freight costs, R&D centre in service by mid-2027, Liaoning base as the group's high-value technology-transformation platform, and deleveraging via CB proceeds.

Consensus growth expectations

Not publicly disclosed (no sell-side consensus identified). The company's own illustrative scenarios in the CB dilution filing (flat, +10% and +20% annual net profit growth from CNY 77.82M) are explicitly not forecasts. For reference, simple annualisation of 1H2026 implies revenue of ~CNY 1.5–1.6bn for FY2026 if seasonality mirrors prior years (analyst arithmetic, not a forecast).

Bull case

  1. Operating inflection is already visible: 1H2026 gross profit rose 27% on 13% revenue growth, with overseas gross margin up ~3pp to 20.4% and opex down; once FX normalises, the operating leverage flows through to earnings.

  2. Mix migration to HPP: Heterocyclic pigments grew 31% and the CB-funded post-treatment project targets exactly the higher-margin performance segment where Western capacity (Heubach) has exited.

  3. Moat plus valuation support: An 11-year export-leadership record, 89 REACH registrations and decade-long blue-chip relationships underpin a franchise trading at ~2.2x EV/Sales and ~3x P/B — far below theme-driven peers such as Lily (~10x P/B).

Bear case

  1. Capital allocation is eroding returns: ROE fell from ~18% (FY2024) to ~9.5% (FY2025, derived) as the asset base doubled; manufacturing subsidiaries remain loss-making and projects are repeatedly delayed.

  2. FX, tariffs and freight are structural, not cyclical: With 80%+ of revenue overseas, a CNY 36M FX swing on CNY 65M of pre-tax profit (1H2026) shows earnings are hostage to macro variables the company cannot control.

  3. Valuation is not cheap on earnings: ~40x TTM P/E for a business with ~6% net margins, flat five-year revenue (2.1% CAGR), under 1% R&D intensity and an incoming CB of up to ~14% of market cap; 20% of float is margin-financed, amplifying downside.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Late Oct 20263Q2026 results — test of whether revenue growth and margin gains persist and FX losses moderate
4Q2026–1H2027SZSE review and CSRC registration of the ≤ CNY 450M CB; coupon, conversion price and rating
2H2026–1H2027Completion of the 1,500 t organic pigment project (92% done) and Liaoning loss trajectory (minority-share losses as proxy)
By 30 Jun 2027R&D Centre & HQ completion (any third delay would damage credibility)
OngoingUSD/CNY and EUR/CNY; US tariff actions on Chinese chemicals; China–Europe/US container rates
Apr 2027FY2026 annual report and dividend decision
OngoingRelated-party purchases from Wenzhou Jinyuan versus the CNY 92M cap
OngoingMargin-financing balance and shareholder count as sentiment indicators

Analyst verdict

Trust Chem is a genuinely differentiated asset within China's crowded pigment sector: it is not the largest producer, but it is the most internationally embedded, with a decade-plus record as the country's leading exporter, a regulatory compliance apparatus that few domestic peers can match, and customer relationships with the world's top ink and coatings formulators. That franchise generated attractive, capital-light returns — derived ROE of roughly 17–22% through FY2024 — on a business that has nonetheless never grown much: revenue in FY2025 was only about 9% above FY2021.

The company is now making a deliberate, and costly, bet that vertical integration will solve its core structural weakness — thin margins inherent to a trading model. The evidence so far is mixed. On the positive side, 1H2026 delivered the strongest gross-profit growth since listing, a visible shift toward high-performance heterocyclic pigments and margin expansion overseas. On the negative side, the Liaoning manufacturing subsidiaries remain loss-making, the IPO-funded R&D headquarters has been delayed twice, return on equity has roughly halved, and the company is returning to the market for up to CNY 450M only fifteen months after its IPO, after describing its first raise as too small.

Reported earnings remain highly sensitive to the renminbi, freight and US tariffs — none of which management can control — and at roughly 40 times trailing earnings, the shares already discount a successful transition. The stock has de-rated sharply from its first-day euphoria, and its tightly held, retail- and margin-dominated register adds volatility.

Verdict: Neutral / "show-me" stance. The franchise is real and the operating trend is improving, but the investment case requires proof that manufacturing integration lifts consolidated gross margin sustainably above ~20% and restores ROE toward mid-teens without excessive dilution. The 3Q2026 results, CB terms and Liaoning profitability are the decisive monitorables over the next twelve months.


Data limitations: The FY2025 annual report full text (segment detail, FY2025 cash flow, R&D and EBITDA) and FY2021–FY2025 annual R&D figures were not available in the sources reviewed; such items are marked accordingly. Market data are as of the latest verified quote (1 Sep 2026) and should be refreshed. Derived figures are analyst computations from disclosed data.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenure / startBackgroundAge / bornEducation

Li Zhi (李治)

Chairman & General Manager; legal representative

Founder (1996); Chairman since Sep 2021

Sales manager, China National Chemicals Import & Export Corp. Zhejiang branch (1991–94); senior manager, Hong Kong Longyuan Trading (1994–96); executive director/GM of predecessor (1996–2021); also chairs Liaoning Xinkai and Liaoning Ziyuan; director of Xinkai Senyuan, Haochuan, BOSON

Born Oct 1969 (56–57)

MBA, Zhejiang University of Technology; HK permanent residency

Li Wu (李武)

Director & Technical Director

Co-founder (1996)

Teacher, School of Biological & Chemical Engineering, Zhejiang University of Science & Technology (since 1986); technical director of predecessor (1996–2021); vice-chair of Liaoning Xinkai and Liaoning Ziyuan; director of Wenzhou Jinyuan and BOSON; former chairman of Anshan Huihong New Materials

Born Jul 1967 (59)

Diploma in chemical engineering, Zhejiang University of Science & Technology; study at Emden-Leer University (Germany) 1993–94

Liu Jianbing (刘建兵)

Director & CFO (head of accounting)

————

Jiang Wei (蒋炜)

Director & HR/Administration Director

——

Born Sep 1980

—

Shen Rijiong (沈日炯)

Independent Director

————

Shi Fang (施放)

Independent Director

————

Liang Weiliang (梁伟亮)

Independent Director (accounting expert)

—

CFO, Hangzhou Hexing Electric (2015–17); director & CFO, Borui Energy Environmental Engineering (2017–20); VP, Fancheng Design (2020–22); director, Zhejiang Samsung Thermal Power

Born Nov 1973

BA Accounting, Zhejiang University of Finance & Economics; senior accountant; non-practising CICPA member

Huang Tao (黄涛)

Board Secretary & Procurement Manager

————

Sun Xucong (孙旭聪)

Head of Accounting Department

————

Yang Qinhua (杨沁桦)

Securities Affairs Representative

————

“—” = not publicly disclosed.

Board of Directors (Annual)

NameRoleFY2024 total payFY2025 total pay

Li Zhi

Chairman & GM

851.31,048.1

Li Wu

Director & Technical Director

577.5698.8

Liu Jianbing

Director & CFO

596.8—

Jiang Wei

Director & HR/Admin Director

562.0—

Shen Rijiong

Independent Director

78.0—

Shi Fang

Independent Director

78.0—

Liang Weiliang

Independent Director

78.0—

Huang Tao

Board Secretary

375.4—

Major Shareholders

RankShareholderTypeSharesStake %Restricted until
1

Zhejiang Xinkai Senyuan Investment (Li Zhi 65%, Li Wu 35%)

Domestic non-state legal person

40,000,00042.67

15 Apr 2028

2

Li Zhi

Individual

16,250,00017.34

15 Apr 2028

3

Li Wu

Individual

8,750,0009.33

15 Apr 2028

4

Hangzhou Lishijia Enterprise Management LP (GP: Li Zhi)

Partnership

3,195,5303.41

15 Apr 2028

5

Ningbo Huikai Century Venture Capital LP (formerly Huzhou Huikai)

Partnership

2,106,1402.25

Unrestricted since 15 Apr 2026 (sold 3,000 shares in 1H2026)

6

Feng Wei

Individual (margin account)

832,6000.89—
7

Wu Aijun

Individual

456,1650.49—
8

Tong Zheng

Individual

380,1000.41—
9

Wu Nan

Individual

349,6000.37—
10

Suzhou Hongweisite Electronic Technology

Legal person

307,2000.33—

Competitive Landscape

Key Competitors

CompetitorCountryOverlap with Trust ChemPositioning vs. Trust Chem

Lily Group (百合花, 603823.SH)

China

Azo, phthalocyanine, HPP; inks/coatings/plastics

Integrated manufacturer; claims ~10% global organic-pigment share; larger scale

Anshan Qicai Chemical (七彩化学, 300758.SZ)

China

HPP (benzimidazolone), solvent dyes

Higher-margin HPP manufacturer; also in Liaoning

Shuangle Pigment (双乐股份, 301036.SZ)

China

Phthalocyanine, classic pigments

Manufacturer; first-tier domestic

Longkou Union Chemical (联合化学, 301209.SZ)

China

Azo/classic pigments

Manufacturer; first-tier domestic

Changshan Beiming / Sunshine Pigment / Jiehong Pigment

China

Classic pigments

Second-tier domestic producers

Sun Chemical (DIC Group)

Japan/US

Full range (incl. former BASF pigments acquired 2021)

Global leader — and a Trust Chem customer (co-opetition)

Heubach Group (incl. former Clariant pigments)

Germany

Full range incl. HPP

—

Sudarshan Chemical Industries

India

Organic pigments

Consolidator post-Heubach; global reach

Indian classic-pigment exporters (e.g., Meghmani-type producers)

India

Azo/phthalocyanine exports

Price competitors in export markets

Toyocolor (artience Group)

Japan

Pigments for inks/plastics

Asian incumbent

Peer Comparison FY2025

MetricTrust Chem (001335)Lily Group (603823)Qicai Chemical (300758)

1Q2026 revenue (CNY Mn)

382.1573401

Revenue YoY (%)

+8.92+0.74+9.77

1Q2026 net profit (CNY Mn)

24.24316

Net profit YoY (%)

+3.05−6.22−48.64

Net margin (%, derived)

6.37.54.0

Gross margin (%)

not disclosed for 1Q (1H2026: 18.27)

20.0229.19

Market cap (CNY Bn, Jul 2026)

~2.8–3.1

~25.2

~3.6

P/E (TTM / dynamic)

~36–40

~147 (dynamic)

~58 (dynamic)

R&D intensity

~1% (1H2026)

——

Company Snapshot

$182.6M

Revenue

445

Employees

1996

Founded

Zhejiang, China

Headquarters

SWOT Analysis

Strengths

  • Export leadership: Ranked No. 1 Chinese organic-pigment exporter every year 2015–2025 (China Dyestuff Industry Association; 2026 Interim Report).
  • Regulatory moat: 89 EU REACH registrations completed in-house, MSDS in ~30 languages (2026 Interim Report).
  • Blue-chip customers: DIC, Flint, Siegwerk, Sherwin-Williams, Axalta, with 10+ year tenure (CB feasibility report, Jul 2026).
  • Global logistics footprint: Six overseas warehouses plus a 5,500 m² Shanghai hub; Europe and US subsidiaries alone generated CNY 316M revenue in 1H2026 (2026 Interim Report).
  • Historically high capital efficiency: Derived ROE of 21.7%/17.5%/18.3% in FY2022–FY2024 on a capital-light model (audited data, IPO announcement).
  • Solid liquidity: Current ratio 1.57x and liabilities-to-assets 45.3% at 1Q2026; no top-holder share pledges (CB plan; 2026 Interim Report).
  • Improving mix: Heterocyclic (HPP) revenue +31.1% in 1H2026 to 22.4% of sales (2026 Interim Report).

Weaknesses

  • Low gross margin: ~14.3% (FY2024) and 18.3% (1H2026) versus Qicai 29.2% and Lily 20.0% (1Q2026).
  • Low R&D intensity: 0.97% of revenue in 1H2026; parent reports zero R&D expense (2026 Interim Report).
  • Supplier dependence: Purchased finished goods 88.9–94.9% of cost FY2021–1H2024 (IPO announcement).
  • Loss-making manufacturing: Liaoning Xinkai FY2024 net loss CNY 24.97M on revenue of CNY 100.56M (guarantee announcement 2025-016).
  • Project execution slippage: R&D Centre & HQ delayed twice (Dec 2025 → Sep 2026 → Jun 2027) (2026 Interim Report; Sep 2026 announcement).
  • Governance concentration: Combined Chair/CEO; 72.75% held by founders' concert party; minimal institutional ownership (2026 Interim Report).
  • Negative free cash flow: 1H2026 OCF CNY 39.7M versus capex CNY 68.7M (2026 Interim Report).

Opportunities

  • Western capacity exit: Heubach's 2024 insolvency removed a ~10%-share HPP player (press reports).
  • Value-add via post-treatment: CNY 230M CB project could upgrade outsourced pigments to higher-margin grades (CB feasibility report).
  • Domestic market: Domestic revenue +70% in 1H2026 to CNY 147M (2026 Interim Report).
  • Regulation-driven substitution: "New, safe and environmentally friendly pigments and dyes" listed in China's key supported high-tech fields (CB report); EU REACH tightening.
  • Digitalisation: CNY 20M ERP rebuild to integrate 15 entities and enable AI tools (CB report).
  • Margin recovery: Overseas gross margin +2.96pp to 20.41% in 1H2026, showing pass-through capability (2026 Interim Report).

Threats

  • Currency: 1H2026 finance costs swung by CNY 36M year-on-year, mainly on RMB appreciation (2026 Interim Report).
  • Tariffs: US tariffs on the company's pigments since 2018; US was 14.4% of main revenue in 1H2024 (IPO announcement).
  • Freight: Red Sea disruption and record spot rates in 2026 (2026 Interim Report risk section).
  • Feedstock volatility: Petrochemical and coal-chemical input costs (2026 Interim Report).
  • Dilution and leverage: ≤ CNY 450M CB equals ~14% of market cap at Sep 2026 price (derived).
  • Integrated competitors: Lily, Qicai and Indian producers moving down the chain toward direct export relationships.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
7 Apr 2025Zhonghui CPA verifies IPO proceeds of CNY 299.97M gross / CNY 243.85M netCapital raised
15 Apr 2025Listing on SZSE Main Board at CNY 12.80; opens at CNY 51Became public; extreme first-day premium set later de-rating path
29 Apr 20251Q2025 report: revenue ≈ CNY 350.8M, attributable NP ≈ CNY 23.5M (derived from 1Q2026 growth rates); prepayments +97%, export-tax-rebate receivables +47%Solid start; working-capital build
9 May 2025Board approves replacement of CNY 57.42M pre-invested own fundsRoutine post-IPO housekeeping
1 Jun 2025Shanghai Fengxian 5,500 m² logistics centre lease begins (3 years)Logistics capacity
3 Jun 2025Board approves FY2024 dividend CNY 0.15/share, CNY 1.2bn credit line, guarantees up to CNY 300M for Liaoning Xinkai, FX hedgingCapital framework
25 Jun 2025FY2024 AGM approves all resolutions (credit/guarantee resolution 99.93% for)Governance
Aug 20251H2025: revenue CNY 699.08M (+4.91%), attributable NP CNY 54.57M (+18.47%), deducted NP CNY 61.32M (+37.96%)Peak post-IPO earnings momentum
2025 (H2)Participation in European Coatings Show (Nuremberg) and Chinaplas promotedMarketing
30 Sep 2025New guarantee lines approved: CNY 270M and CNY 400M (Liaoning Xinkai), CNY 280M (Liaoning Ziyuan)Scaling manufacturing financing
15 Oct 2025Offline placement lock-up (471,269 shares) expiresMinor float increase
27 Oct 2025CNY 120M guarantee drawn for Liaoning XinkaiLeverage at subsidiary
Late 2025R&D Centre & HQ completion date moved from 31 Dec 2025 to 30 Sep 2026 (site excavation stoppage, slow municipal roads, custom equipment)First project delay
19 Dec 2025Haochuan Technology HNTE certification renewed (GR202533005999)15% tax rate preserved
24 Dec 20252026 related-party purchase cap of CNY 92M with Wenzhou Jinyuan announcedRelated-party dependence
25 Dec 2025CNY 100M guarantee drawn for Liaoning Ziyuan (to 2035)Long-dated project financing
13 Mar 2026On-site visit by ~15 investors (Huaan Securities, Industrial Securities, First Capital, private funds)Sell-side/buy-side interest
Apr 2026FY2025 results: revenue CNY 1.313bn (−7.33%), attributable NP CNY 77.82M (−29.87%), deducted NP CNY 83.02MFirst annual decline post-IPO
Apr 20261Q2026: revenue CNY 382.1M (+8.92%), attributable NP CNY 24.21M (+3.05%), OCF −CNY 31.92MRevenue recovery
15 Apr 2026Pre-IPO VC (Ningbo Huikai) lock-up expires: 2,109,140 sharesOverhang; minimal selling to date
15 Apr 2026CNY 50M guarantee drawn for Liaoning XinkaiContinued subsidiary funding
29 Apr 2026Board approves 2026 FX derivative hedgingRisk management
18 May 2026FY2025 online results briefing (operations, project progress, dividend)IR
21 May 2026FY2025 AGM approves CNY 0.15/share dividend and director payPayout maintained despite profit fall
7–8 Jul 2026Board approves ≤ CNY 450M convertible bond planMajor financing; stock −30.9% YTD at the time
29 Jul 2026Third EGM of 2026 held (resolution announcement filed; timing consistent with CB approval)Governance
24 Aug 20261H2026: revenue +13.23%, attributable NP +0.92%, deducted NP −14.29%, FX-driven finance charge CNY 18.9MOperating recovery masked by FX
23 Sep 2026Second delay of R&D Centre & HQ to 30 Jun 2027 (imported custom equipment lead times); 68.03% invested at 31 AugExecution slippage

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

8 charts
Income Statement: Revenue & Gross Profit: Revenue rose from CNY 699.1 Mn in 1H 2025 to CNY 791.6 Mn in 1H 2026.
Trust Chem Co. Ltd. — Income Statement: Revenue & Gross Profit
Series (CNY Mn)1H 20251H 2026
Revenue699.1791.6
Cost of sales585.5646.9
Gross profit113.6144.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.